This updated analysis supports the benefits of incretin-based therapies, SGLT2 inhibitors, and finerenone in reducing cardiorenal events across diverse populations, particularly those with T2D, ASCVD, CKD, and HF. This evidence concerns the gene GCG and hydrops fetalis.